Diabetic Ulcer
10
1
1
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
20.0%
2 terminated out of 10 trials
66.7%
-19.8% vs benchmark
20%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
Fetal Cell Receptors Repertoire
Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds
The RESPOND Registry
PuraPly™ Antimicrobial Wound Matrix and Wound Management
Evaluation of Lower Extremity Tissue Perfusion With Polarized Laser Light
Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers
Evaluation of Topical Wound Oxygen (two2) Therapy
Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers
Treatment of Wounds Utilizing Light
Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers